TY  - JOUR
AU  - Hernandez, Maria V
AU  - Sanchez-Piedra, Carlos
AU  - Garcia-Magallon, Blanca
AU  - Cuende, Eduardo
AU  - Manero, Javier
AU  - Campos-Fernandez, Cristina
AU  - Martin-Domenech, Raquel
AU  - Del Pino-Montes, Javier
AU  - Manrique, Sara
AU  - Castro-Villegas, Maria C
AU  - Ruiz-Montesinos, Dolores
AU  - Sanchez-Alonso, Fernando
AU  - Diaz-Gonzalez, Federico
AU  - Cea-Calvo, Luis
AU  - Gomez-Reino, Juan J
PY  - 2018
DO  - 10.1007/s00296-018-4177-z
UR  - http://hdl.handle.net/10668/13124
T2  - Rheumatology international
AB  - The retention rate of a biological drug (percentage of patients remaining on treatment over time) provides an index of a drug's overall effectiveness. The golimumab retention rate as first-line biological therapy was high in clinical trial extensions...
LA  - en
PB  - Springer
KW  - Ankylosing spondylitis
KW  - Axial spondyloarthritis
KW  - Golimumab
KW  - Medication retention rate
KW  - Psoriatic arthritis
KW  - Rheumatoid arthritis
KW  - Adrenal Cortex Hormones
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Antirheumatic Agents
KW  - Arthritis, Psoriatic
KW  - Arthritis, Rheumatoid
KW  - Drug Therapy, Combination
KW  - Female
KW  - Humans
KW  - Male
KW  - Medication Adherence
KW  - Methotrexate
KW  - Middle Aged
KW  - Proportional Hazards Models
KW  - Registries
KW  - Retrospective Studies
KW  - Spain
KW  - Spondylarthropathies
KW  - Tumor Necrosis Factor Inhibitors
TI  - Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry.
TY  - research article
VL  - 39
ER  -